Expanding therapeutic options targeting claudin-18.2

Mené sur 134 patients atteints d'un cancer avancé de l'estomac ou de la jonction oesogastrique, cet essai multicentrique de phase I évalue l'activité antitumorale et la sécurité de CMG901, un conjugué anticorps-médicament ciblant la protéine Claudine 18.2

Résumé en anglais

Therapeutic options for patients with advanced gastric or gastro-oesophageal junction adenocarcinomas are rapidly evolving.1 Although chemotherapy alone results in a median survival of less than a year, the majority (approximately 75%) of gastric and gastrooesophageal junction adenocarcinoma tumours express molecular targets that are amenable to personalised antibody-based therapies.2 These targeted treatments, if combined with cytotoxic chemotherapy, extend overall survival. Established monoclonal antibody targets include HER2 (also known as ERBB2) and PD-L1, with claudin-18.2 (CLD18.2) emerging as an addition within the past year. Zolbetuximab, a first-in-class monoclonal antibody targeting CLD18.2, improved overall survival when added to platinum-fluoropyrimidine chemotherapy in patients with CLD18.2-positive, advanced, untreated gastric or gastro-oesophageal junction adenocarcinoma.3 The positive results of SPOTLIGHT and GLOW validate CLD18.2 as a therapeutic target and established a basis for an expansive pipeline of next-generation CLD18.2-directed therapies.